Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Dr. Fleur-Lominy on Targeted Pathways in MPNs

June 15th 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses targeted pathways in myeloproliferative neoplasms.

Real-World Evidence Supports Ruxolitinib Reinitiation in Myelofibrosis

June 10th 2020

Naveen Pemmaraju, MD, discusses the potential benefit of rechallenging ruxolitinib in patients with myelofibrosis.

Dr. Bose on the Management of Patients With Myelofibrosis Who Progress on Ruxolitinib

June 9th 2020

Prithviraj Bose, MD, discusses management strategies for patients with myelofibrosis who progress on ruxolitinib (Jakafi).

Dr. Bose on the Management of Patients With Myelofibrosis Who Progress on Ruxolitinib

June 8th 2020

Prithviraj Bose, MD, associate professor in the Department of Leukemia of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses management strategies for patients with myelofibrosis who progress on ruxolitinib (Jakafi).

Dr. Bose on the Utility of Ruxolitinib in Myelofibrosis

June 6th 2020

Prithviraj Bose, MD, discusses the utility of ruxolitinib in patients with myelofibrosis.

Dr. Hoffman on the Current Polycythemia Vera Treatment Paradigm

June 5th 2020

Ronald Hoffman, MD, discusses the current polycythemia vera treatment paradigm.

Dr. Mascarenhas on the Impact of Ruxolitinib on the Myelofibrosis Treatment Paradigm

June 5th 2020

John O. Mascarenhas, MD, discusses the impact of ruxolitinib in the myelofibrosis treatment paradigm.

FDA Accepts Application for Ropeginterferon Alfa-2b for Polycythemia Vera

June 5th 2020

The FDA has accepted an application for ropeginterferon alfa-2b for use as a treatment for patients with polycythemia vera.

Dr. Cortes on Future Directions in MPNs

June 3rd 2020

Jorge E. Cortes, MD, discusses challenges with ruxolitinib in myeloproliferative neoplasms.

Hepcidin Mimetic PTG-300 Shows Early Promise in Polycythemia Vera

May 19th 2020

The first-in-class, synthetic hepcidin mimetic agent PTG-300 is being investigated in an ongoing phase 2 clinical trial, with the goal of introducing a novel therapeutic agent to the limited armamentarium in polycythemia vera.

Ruxolitinib Discontinuation in Myelofibrosis Leads to Increased Morbidity Burden, Underscoring Unmet Need

May 18th 2020

John O. Mascarenhas, MD, discusses patient characteristics and outcomes following ruxolitinib discontinuation in myelofibrosis and research efforts being made to address a large unmet need in the space.

Alvocidib Trial Launches in MDS

May 14th 2020

The first patient has been diagnosed with alvocidib, administered in sequence following azacitidine, in the expansion of the phase 1b/2 Zella 102 study in patients with myelodysplastic syndromes.

Dr. Bose on Novel Agents Under Investigation in Myelofibrosis

May 14th 2020

Prithviraj Bose, MD, discusses novel agents under investigation in myelofibrosis.

Research Swells in Myelofibrosis With JAK Inhibitors, Novel Agents

May 13th 2020

Prithviraj Bose, MD, discusses the role of ruxolitinib in myelofibrosis, the potential advantages of next-generation JAK inhibitors, and other novel agents under exploration.

Research Swells in Myelofibrosis With JAK Inhibitors, Novel Agents

May 13th 2020

Prithviraj Bose, MD, discusses the current role of ruxolitinib in myelofibrosis, the potential advantages of next-generation JAK inhibitors, and the novel agents that are being explored as single agents and in combination with ruxolitinib.

New MDS Subtype Recognized Based on Presence of Common Genetic Variant

May 8th 2020

The International Working Group for the Prognosis of MDS has identified a distinct subtype of myelodysplastic syndromes based on the presence of SF3B1, a nonheritable genetic mutation that causes the disease.

Dr. Michaelis on the Role of Interferon in MPNs

May 4th 2020

Laura C. Michaelis, MD, discusses the role of interferon in myeloproliferative neoplasms.

EU Panel Backs Luspatercept for Anemia in MDS and Beta Thalassemia

May 1st 2020

A European panel has recommended approval of luspatercept for the treatment of anemia in patients with myelodysplastic syndromes and beta thalassemia.

Dr. Bradley on the Utility of Ruxolitinib in Myelofibrosis and Polycythemia Vera

April 28th 2020

Terrence J. Bradley, MD, discusses the utility of ruxolitinib (Jakafi) in myelofibrosis and polycythemia vera.

Dr. Fleur-Lominy on the Current Sequencing Strategy in MPNs

April 28th 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses the current sequencing strategy in the treatment of patients with myeloproliferative neiplasms.